Skip to content
Screener

Innoviva, Inc. INVA Total Revenue

Total Revenue at other companies

Pfizer logo
PfizerPFE
$15.03B+2.6%
Merck & Co. logo
Merck & Co.MRK
$16.61B+5.1%
AbbVie logo
AbbVieABBV
$16.99B+10.2%
Insmed logo
InsmedINSM
$425.49M+296%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$17.7M+15.0%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$29.11M-2.1%

Segments

By product

See full
Giapreza$22.3M+28.7%
Cost Reimbursement$1.8M+125%

Other financials

Income statement

See full
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Royalty revenue, net of amortization of capitalized fees paid of $3,456 in the three months ended June 30, 2026 and 2025, and $6,912 in the six months ended June 30, 2026 and 2025$56,334$63,880$111,501$121,687
Net product sales51,77135,49393,14265,772
License and other revenue11,48691012,9421,456
Total revenue119,591100,283217,585188,915
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)22,34910,59037,95619,432
Amortization of acquired intangible assets6,6266,54713,18013,022
Gross profit90,61683,146166,449156,461
Operating expenses:

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s total revenue?
Innoviva, Inc. (INVA) reported total revenue of $119.59M in Q2 2026.
How has Innoviva, Inc.'s total revenue changed year-over-year?
Innoviva, Inc.'s total revenue increased by 19.3% year-over-year, from $100.28M to $119.59M.
What is the long-term trend for Innoviva, Inc.'s total revenue?
Over 4 years (2021 to 2025), Innoviva, Inc.'s total revenue has grown at a 1.2% compound annual growth rate (CAGR), from $391.87M to $411.33M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Innoviva, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude